# Payers fund cancer drugs conditionally on a registry with a pre-specified analysis

Source: https://onco.cc/ideas/idea-data-coverage-with-evidence-development/  
OnCo record `idea-data-coverage-with-evidence-development` (Idea). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

When a health system pays for a new, uncertain cancer drug, it would require that every patient's outcome is recorded and that a pre-agreed analysis decides whether payment continues.

## Summary

Coverage with evidence development exists (the English Cancer Drugs Fund, Medicare CED, Italy's AIFA registries) but analyses are often weak, late or never published. The proposal standardises the model: a pre-registered statistical analysis plan agreed at listing, mandatory structured data capture, an independent analysis body, a fixed decision date, and publication of results whatever the outcome.

## Fields

- Kind: Idea
- Last checked: 2026-09-08
- Hypothesis: Standardised CED with pre-specified analyses will produce a reimbursement decision for more than 90 percent of conditionally funded indications within three years, and will lead to withdrawal or price reduction in a meaningful share.
- Rationale: The reformed Cancer Drugs Fund (2016) cleared its backlog by fixing decision dates and data collection; AIFA registries have supported outcome-based rebates. Standardising the analytic component is the missing piece.
- Proposed test: Audit all CED decisions in three systems over five years for timeliness and publication; introduce the standardised model in one and compare.
- Maturity: being-tested-at-scale
- Actor: payer

## Sources

- NICE Cancer Drugs Fund: https://www.england.nhs.uk/cancer/cdf/

## Connected records

- fronts: [AI & Computation](https://onco.cc/fronts/ai-computation/)
- terms: [Real-world evidence](https://onco.cc/terms/real-world-evidence/)
- bottlenecks: [Prices and value](https://onco.cc/bottlenecks/b-drug-pricing/), [Weak real-world evidence and registries](https://onco.cc/bottlenecks/b-real-world-evidence/)
- ideas: [Reassess cancer drug prices at three years using real-world outcomes](https://onco.cc/ideas/idea-data-outcome-based-price-reassessment/)

---
JSON: https://onco.cc/api/v1/entities/idea-data-coverage-with-evidence-development.json